Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer.

about

Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer.

Item

http://www.wikidata.org/entity/Q40782810

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Concurrent Diabetes Mellitus m ...... with Advanced Prostate Cancer.

@en

type

Item

label

Concurrent Diabetes Mellitus m ...... with Advanced Prostate Cancer.

@en

prefLabel

Concurrent Diabetes Mellitus m ...... with Advanced Prostate Cancer.

@en

P1476

Concurrent Diabetes Mellitus m ...... with Advanced Prostate Cancer.

@en

P2093

Emily Jane Gallagher

http://www.w3.org/2001/XMLSchema#string

Jeffrey Shevach

http://www.w3.org/2001/XMLSchema#string

Manpreet Brar

http://www.w3.org/2001/XMLSchema#string

Matthew D Galsky

http://www.w3.org/2001/XMLSchema#string

Teena Kochukoshy

http://www.w3.org/2001/XMLSchema#string

Victoria Gresia

http://www.w3.org/2001/XMLSchema#string

William K Oh

http://www.w3.org/2001/XMLSchema#string

P2860

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database.

The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series.

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.

Does pre-existing diabetes affect prostate cancer prognosis? A systematic review.

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

Androgens, insulin resistance and vascular disease in men.

Obesity and prostate cancer: epidemiology and clinical implications.

P304

129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2015.00129

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279629098

http://www.w3.org/2001/XMLSchema#string

P698

26125012

http://www.w3.org/2001/XMLSchema#string

P932

4467174

http://www.w3.org/2001/XMLSchema#string